WB | 咨询技术 | Mouse, Human |
IF | 咨询技术 | Mouse, Human |
IHC | 1/20-1/100 | Mouse, Human |
ICC | 技术咨询 | Mouse, Human |
FCM | 咨询技术 | Mouse, Human |
Elisa | 咨询技术 | Mouse, Human |
Host/Isotype | Rat IgG2a |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Mouse, Human |
Immunogen | Purified recombinant fragment of mouse Cmtm6 |
Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于Cmtm6抗体的参考文献概览:
1. **"Cmtm6 maintains the expression of PD-L1 and regulates anti-tumour immunity"**
*作者:Burr et al. (Nature, 2017)*
摘要:首次揭示Cmtm6通过结合PD-L1并阻止其溶酶体降解,维持肿瘤细胞表面PD-L1蛋白稳定性,为免疫检查点抑制剂的耐药机制提供新解释,研究中使用了Cmtm6抗体进行免疫共沉淀实验。
2. **"CMTM6 modulates PD-L1 expression by antagonizing EGFR-mediated ubiquitination in melanoma"**
*作者:Yang et al. (Cancer Research, 2021)*
摘要:证明Cmtm6通过抑制EGFR对PD-L1的泛素化降解通路增强其表达,研究中采用Cmtm6特异性抗体进行免疫荧光染色,揭示其在黑色素瘤微环境中的空间表达模式。
3. **"CRISPR screens identify CMTM6 as a therapeutic target in PD-L1-positive cancers"**
*作者:Jiang et al. (Cell Reports, 2020)*
摘要:通过CRISPR筛选发现Cmtm6是PD-L1阳性肿瘤的潜在治疗靶点,研究使用Cmtm6抗体验证基因敲除后PD-L1蛋白水平下降,并证明联合抗Cmtm6与PD-1抑制剂可增强抗肿瘤效果。
*注:以上文献均为肿瘤免疫治疗领域的高影响力研究,Cmtm6抗体主要用于机制验证实验(如WB、IP、IF),尚未见直接针对Cmtm6的治疗性抗体开发文献。*
×